NDLI: In silico ligand-based pharmacophore model generation for the identification of novel Pneumocystis carinii DHFR inhibitors

Content Provider	Springer Nature Link
Author	Kiani, Yusra Sajid Kalsoom, Saima Riaz, Naveeda
Copyright Year	2012
Abstract	The ubiquitous enzyme, dihydrofolate reductase (DHFR), is a well-studied metabolic enzyme of significant pharmacological relevance. The past research studies have shown that DHFR has emerged as an important therapeutic target for the treatment of various diseases including cancers, bacterial and protozoal infections, and the opportunistic infections that are associated with AIDS. DHFR has been successfully used and selected as a target for the purpose of devising a cure for various diseases by discovering the antimicrobial drugs against a range of pathogenic microorganisms including the opportunistic microorganisms Pneumocystis carinii (pc), Toxoplasma gondii and Mycobacterium avium complex. However, it has been reported that blockage of the enzymatic activity of DHFR is a crucial and most significant element in terms of the treatment of a wide range of diseases. DHFR is also a key enzyme in the treatment of Pneumocystosis. The discovery and development of type-specific pcDHFR inhibitors is of both research and clinical interests. Ligand-based pharmacophore modeling is playing a vital role for the identification of ligand features for the particular targets. In this study, we present a model for the design of ligand-based pharmacophore onto the set of 10 compounds of eight different classes along with the standard drug trimethoprim. The ligand-based pharmacophore model has been identified to facilitate the discovery of type-specific pcDHFR inhibitors. A pharmacophore model was generated using Ligand Scout 3.02 with diverse classes of pcDHFR inhibitors. The proposed pharmacophore model generated in this study revealed that the model contains two HBAs, two HBDs, and one HY/AR volume. Ligand Scout 3.02 has been used to predict the pharmacophore features for pcDHFR inhibitors, and the distances between pharmacophore features have been computed by the effective use of the software VMD. The results indicate that the in silico methods are valuable for the prediction of the biological activity of the compound or compound library by screening it against a predicted pharmacophore. Thus, the results obtained in this study can be considered to be useful and reliable tools for the identification of structurally diverse compounds with the desired biological activity. The model has also been validated, firstly by mapping of five test compounds on to our model and secondly by docking these test compounds into the active site of pcDHFR.
Starting Page	949
Ending Page	963
Page Count	15
File Format	PDF
ISSN	10542523
Journal	Medicinal Chemistry Research
Volume Number	22
Issue Number	2
e-ISSN	15548120
Language	English
Publisher	Springer-Verlag
Publisher Date	2012-05-30
Publisher Place	New York
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Dihydrofolate reductase Pneumocystis carinii pneumonia Pneumocystis carinii pcDHFR inhibitors Pharmacophore Therapeutic agents Ligand Scout Ligand Scout 3.02 Visual Molecular Dynamics VMD Pharmacology/Toxicology Biochemistry Cell Biology
Content Type	Text
Resource Type	Article
Subject	Organic Chemistry Pharmacology, Toxicology and Pharmaceutics

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

In silico pharmacophore model generation for the identification of novel butyrylcholinesterase inhibitors against Alzheimer’s disease

Application of DNA Amplification to Pneumocystosis: Presence of Serum Pneumocystis carinii DNA During Human and Experimentally Induced Pneumocystis carinii Pneumonia

Dihydrofolate reductase-like protein inactivates hemiaminal pharmacophore for self-resistance in safracin biosynthesis.

Ligand-based 3D-QSAR analysis and virtual screening in exploration of new scaffolds as Plasmodium falciparum glutathione reductase inhibitors

Interaction Energy Analysis of Nonclassical Antifolates with Pneumocystis carinii Dihydrofolate Reductase

Selective Non-toxics Inhibitors Targeting DHFR for Tuberculosis and Cancer Therapy: Pharmacophore Generation and Molecular Dynamics Simulation

Elaborate ligand-based modeling reveals new human neutrophil elastase inhibitors

Pharmacopore hypothesis generation of BACE-1 inhibitors and pharmacophore-driven identification of potent multi-target neuroprotective agents

A combined 3D QSAR and pharmacophore-based virtual screening for the identification of potent p38 MAP kinase inhibitors: an in silico approach

In silico ligand-based pharmacophore model generation for the identification of novel Pneumocystis carinii DHFR inhibitors

Similar Documents

In silico pharmacophore model generation for the identification of novel butyrylcholinesterase inhibitors against Alzheimer’s disease

Application of DNA Amplification to Pneumocystosis: Presence of Serum Pneumocystis carinii DNA During Human and Experimentally Induced Pneumocystis carinii Pneumonia

Dihydrofolate reductase-like protein inactivates hemiaminal pharmacophore for self-resistance in safracin biosynthesis.

Ligand-based 3D-QSAR analysis and virtual screening in exploration of new scaffolds as Plasmodium falciparum glutathione reductase inhibitors

Interaction Energy Analysis of Nonclassical Antifolates with Pneumocystis carinii Dihydrofolate Reductase

Selective Non-toxics Inhibitors Targeting DHFR for Tuberculosis and Cancer Therapy: Pharmacophore Generation and Molecular Dynamics Simulation

Elaborate ligand-based modeling reveals new human neutrophil elastase inhibitors

Pharmacopore hypothesis generation of BACE-1 inhibitors and pharmacophore-driven identification of potent multi-target neuroprotective agents

A combined 3D QSAR and pharmacophore-based virtual screening for the identification of potent p38 MAP kinase inhibitors: an in silico approach

In silico ligand-based pharmacophore model generation for the identification of novel Pneumocystis carinii DHFR inhibitors